Desmoplastic malignant mesothelioma of the pleura.
Chen LH, Huang CY, Huang SF.
Am J Med Sci. 2022 Oct;364(4):e2-e3. doi: 10.1016/j.amjms.2022.05.002. Epub 2022 May 11.
Guidelines for Pathologic Diagnosis of Mesothelioma: 2023 Update of the Consensus Statement From the International Mesothelioma Interest Group.
Husain AN, Chapel DB, Attanoos R, Beasley MB, Brcic L, Butnor K, Chirieac LR, Churg A, Dacic S, Galateau-Salle F, Hiroshima K, Hung YP, Klebe S, Krausz T, Khoor A, Litzky L, Marchevsky A, Nabeshima K, Nicholson AG, Pavlisko EN, Roden AC, Roggli V, Sauter JL, Schulte JJ, Sheaff M, Travis WD, Tsao MS, Walts AE, Colby TV.
Arch Pathol Lab Med. 2024 Nov 1;148(11):1251-1271. doi: 10.5858/arpa.2023-0304-RA.
Pleural mesothelioma classification-update and challenges.
Dacic S.
Mod Pathol. 2022 Jan;35(Suppl 1):51-56. doi: 10.1038/s41379-021-00895-7. Epub 2021 Aug 31.
Perspectives on the Treatment of Malignant Pleural Mesothelioma.
Janes SM, Alrifai D, Fennell DA.
N Engl J Med. 2021 Sep 23;385(13):1207-1218. doi: 10.1056/NEJMra1912719.
Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma.
Wang Q, Xu C, Wang W, Zhang Y, Li Z, Song Z, Wang J, Yu J, Liu J, Zhang S, Cai X, Li W, Zhan P, Liu H, Lv T, Miao L, Min L, Li J, Liu B, Yuan J, Jiang Z, Lin G, Chen X, Pu X, Rao C, Lv D, Yu Z, Li X, Tang C, Zhou C, Zhang J, Guo H, Chu Q, Meng R, Liu X, Wu J, Hu X, Zhou J, Zhu Z, Chen X, Pan W, Pang F, Zhang W, Jian Q, Wang K, Wang L, Zhu Y, Yang G, Lin X, Cai J, Feng H, Wang L, Du Y, Yao W, Shi X, Niu X, Yuan D, Yao Y, Huang J, Wang X, Zhang Y, Sun P, Wang H, Ye M, Wang D, Wang Z, Hao Y, Wang Z, Wan B, Lv D, Yu J, Kang J, Zhang J, Zhang C, Wu L, Shi L, Ye L, Wang G, Wang Y, Gao F, Huang J, Wang G, Wei J, Huang L, Li B, Zhang Z, Li Z, Liu Y, Li Y, Liu Z, Yang N, Wu L, Wang Q, Huang W, Hong Z, Wang G, Qu F, Fang M, Fang Y, Zhu X, Du K, Ji J, Shen Y, Chen J, Zhang Y, Ma S, Lu Y, Song Y, Liu A, Zhong W, Fang W.
Thorac Cancer. 2023 Sep;14(26):2715-2731. doi: 10.1111/1759-7714.15022. Epub 2023 Jul 17.
Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma.
Tang TT, Konradi AW, Feng Y, Peng X, Ma M, Li J, Yu FX, Guan KL, Post L.
Mol Cancer Ther. 2021 Jun;20(6):986-998. doi: 10.1158/1535-7163.MCT-20-0717. Epub 2021 Apr 13.
Clinical presentation, treatment and outcome of canine malignant mesothelioma: A retrospective study of 34 cases.
Moberg HL, Gramer I, Schofield I, Blackwood L, Killick D, Priestnall SL, Guillén A.
Vet Comp Oncol. 2022 Mar;20(1):304-312. doi: 10.1111/vco.12777. Epub 2021 Oct 25.
Malignant pleural mesothelioma: an update.
Hajj GNM, Cavarson CH, Pinto CAL, Venturi G, Navarro JR, Lima VCC.
J Bras Pneumol. 2021 Dec 13;47(6):e20210129. doi: 10.36416/1806-3756/e20210129. eCollection 2021.
Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review.
Hashimoto K, Okuma Y, Hosomi Y, Hishima T.
BMC Cancer. 2016 Sep 6;16(1):718. doi: 10.1186/s12885-016-2745-8.
Single-cell transcriptomic analysis of human pleura reveals stromal heterogeneity and informs in vitro models of mesothelioma.
Obacz J, Valer JA, Nibhani R, Adams TS, Schupp JC, Veale N, Lewis-Wade A, Flint J, Hogan J, Aresu G, Coonar AS, Peryt A, Biffi G, Kaminski N, Francies H, Rassl DM, Garnett MJ, Rintoul RC, Marciniak SJ.
Eur Respir J. 2024 Jan 25;63(1):2300143. doi: 10.1183/13993003.00143-2023. Print 2024 Jan.
